A novel recombinant human lactoferrin augments the BCG vaccine and protects alveolar integrity upon infection with Mycobacterium tuberculosis in mice
- 5 April 2009
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 27 (23), 3026-3034
- https://doi.org/10.1016/j.vaccine.2009.03.036
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Influence of bovine lactoferrin on expression of presentation molecules on BCG-infected bone marrow derived macrophagesBiochimie, 2008
- Confronting the scientific obstacles to global control of tuberculosisJCI Insight, 2008
- Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune responseGlycoconjugate Journal, 2008
- Peripheral Blood Gamma Interferon Release Assays Predict Lung Responses andMycobacterium tuberculosisDisease Outcome in MiceClinical and Vaccine Immunology, 2008
- Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosisVaccine, 2007
- Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytesMedical Microbiology and Immunology, 2007
- Lactoferrin decreases pollen antigen‐induced allergic airway inflammation in a murine model of asthmaImmunology, 2006
- Causal Vaccine Effects on Binary Postinfection OutcomesJournal of the American Statistical Association, 2006
- A Mutant of Mycobacterium tuberculosis H37Rv That Lacks Expression of Antigen 85A Is Attenuated in Mice but Retains Vaccinogenic PotentialInfection and Immunity, 2004
- Comparison of heparin‐binding to lactoferrin from human milk and from human granulocytes by means of affinity capillary electrophoresisElectrophoresis, 1996